Pah super(e)nu1is a mouse model for tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency and promotes analysis of the pharmacological chaperone mechanism in vivo

The recent approval of sapropterin dihydrochloride, the synthetic form of 6[R]-l-erythro-5,6,7,8-tetrahydrobiopterin (BH sub(4)), for the treatment of phenylketonuria (PKU) as the first pharmacological chaperone drug initiated a paradigm change in the treatment of monogenetic diseases. Symptomatic t...

Full description

Saved in:
Bibliographic Details
Published in:Human molecular genetics 2010-05, Vol.19 (10), p.2039-2049
Main Authors: Gersting, Soeren W, Lagler, Florian B, Eichinger, Anna, Kemter, Kristina F, Danecka, Marta K, Messing, Dunja D, Staudigl, Michael, Domdey, Katharina A, Zsifkovits, Clemens, Fingerhut, Ralph, Glossmann, Hartmut, Roscher, Adelbert A, Muntau, Ania C
Format: Article
Language:English
Subjects:
Animal models
Chaperones
Data processing
Drug development
Drugs
Enzymes
Molecular modelling
Pharmaceuticals
Phenylalanine 4-monooxygenase
Phenylketonuria
Protein folding
Protein structure
sapropterin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recent approval of sapropterin dihydrochloride, the synthetic form of 6[R]-l-erythro-5,6,7,8-tetrahydrobiopterin (BH sub(4)), for the treatment of phenylketonuria (PKU) as the first pharmacological chaperone drug initiated a paradigm change in the treatment of monogenetic diseases. Symptomatic treatment is now replaced by a causal pharmacological therapy correcting misfolding of the defective phenylalanine hydroxylase (PAH) in numerous patients. Here, we disclose BH sub(4) responsiveness in Pah super(e)nu1 a mouse model for PAH deficiency. Loss of function resulted from loss of PAH, a consequence of misfolding, aggregation, and accelerated degradation of the enzyme. BH sub(4) attenuated this triad by conformational stabilization augmenting the effective PAH concentration. This led to the rescue of the biochemical phenotype and enzyme function in vivo. Combined in vitro and in vivo analyses revealed a selective pharmaceutical action of BH sub(4) confined to the pathological metabolic state. Our data provide new molecular-level insights into the mechanisms underlying protein misfolding with loss of function and support a general model of pharmacological chaperone-induced stabilization of protein conformation to correct this intracellular phenotype. Pah super(e)nu1will be essential for pharmaceutical drug optimization and to design individually tailored therapies.
ISSN:0964-6906
1460-2083
DOI:10.1093/hmg/ddq085